Metastatic Liver Cancer - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 89 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Metastatic Liver Cancer - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Metastatic Liver Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Liver Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Liver Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Metastatic Liver Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Liver Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Liver Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Liver Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Metastatic Liver Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Metastatic Liver Cancer - Overview 8
Pipeline Products for Metastatic Liver Cancer - Comparative Analysis 9
Metastatic Liver Cancer - Therapeutics under Development by Companies 10
Metastatic Liver Cancer - Therapeutics under Investigation by Universities/Institutes 12
Metastatic Liver Cancer - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Metastatic Liver Cancer - Products under Development by Companies 15
Metastatic Liver Cancer - Products under Investigation by Universities/Institutes 16
Metastatic Liver Cancer - Companies Involved in Therapeutics Development 17
F. Hoffmann-La Roche Ltd. 17
Celsion Corporation 18
Arrowhead Research Corporation 19
Provectus Biopharmaceuticals, Inc. 20
Transgene Biotek Limited 21
Mirna Therapeutics, Inc. 22
AB Science 23
KAEL-GemVax Co., Ltd. 24
Metastatic Liver Cancer - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
codrituzumab - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
tertomotide - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
masitinib - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Monoclonal Antibody Conjugate Targeting CEA for Metastatic Liver and Colorectal Cancer - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Stem Cell Therapy for Oncology - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
PV-10 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
rRp-450 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MRX-34 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
PSL-001 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
doxorubicin liposomal - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
TBL-0404 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Peptide for Metastatic Liver Cancer - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Metastatic Liver Cancer - Recent Pipeline Updates 53
Metastatic Liver Cancer - Dormant Projects 78
Metastatic Liver Cancer - Discontinued Products 79
Metastatic Liver Cancer - Product Development Milestones 80
Featured News & Press Releases 80
Apr 09, 2014: Celsion's ThermoDox Plus High Intensity Focused Ultrasound Highlighted at 14th International Symposium on Therapeutic Ultrasound 80
Mar 06, 2014: PV-10 Immune Mechanism Data to Be Presented at the American Association for Cancer Research Annual Meeting 81
Oct 24, 2013: Provectus Awarded PV-10 Patent by U.S. Patent and Trademark Office 82
Sep 27, 2012: Provectus Pharma Expands Protocol For Phase I Liver Cancer Study 82
Aug 15, 2012: Delcath Submits New Drug Application For Chemosaturation System To FDA 83
Jun 07, 2012: Celsion To Begin Clinical Study Of ThermoDox For Metastatic Liver Cancer In Collaboration With University Of Oxford 83
Jun 05, 2012: Delcath Systems Presents Post-Hoc Analysis From Phase III Study Of Melphalan 84
Mar 02, 2010: Celsion Plans To Launch Phase II Program To Study ThermoDox In Combination With RFA For Colorectal Liver Metastases 85
Feb 26, 2010: Light Sciences Oncology Meets a Major Milestone in Aptocine Development With Target Enrollment in Phase III MCRC Trial 86
Feb 26, 2010: Light Sciences Oncology Meets a Major Milestone in Aptocine Development With Target Enrollment in Phase III MCRC Trial 86
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 89
Disclaimer 89

List of Tables
Number of Products under Development for Metastatic Liver Cancer, H2 2014 8
Number of Products under Development for Metastatic Liver Cancer - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Metastatic Liver Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 17
Metastatic Liver Cancer - Pipeline by Celsion Corporation, H2 2014 18
Metastatic Liver Cancer - Pipeline by Arrowhead Research Corporation, H2 2014 19
Metastatic Liver Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2014 20
Metastatic Liver Cancer - Pipeline by Transgene Biotek Limited, H2 2014 21
Metastatic Liver Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2014 22
Metastatic Liver Cancer - Pipeline by AB Science, H2 2014 23
Metastatic Liver Cancer - Pipeline by KAEL-GemVax Co., Ltd., H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 29
Number of Products by Stage and Route of Administration, H2 2014 31
Number of Products by Stage and Molecule Type, H2 2014 33
Metastatic Liver Cancer Therapeutics - Recent Pipeline Updates, H2 2014 53
Metastatic Liver Cancer - Dormant Projects, H2 2014 78
Metastatic Liver Cancer - Discontinued Products, H2 2014 79